Science156d left
When will the FDA approve Compass Pathways' COMP360 Psilocybin?
Make a prediction1 vote
Resolution
Criteria
If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2027, then the market resolves to Yes.
Source
Kalshi (kalshi.com)
Recent News
- COMP360, REMS and What FDA Psychedelic Approval Path Means for Investors and Operators - Vicente LLP
Vicente LLP
- Does FDA’s Rolling Review Of COMP360 Psilocybin Depression Therapy Change The Bull Case For COMPASS Pathways (CMPS)? - Yahoo Finance
Yahoo Finance
- FDA Awards Priority Voucher to Compass for Psychedelic Therapy in Treatment-Resistant Depression - Pharmaceutical Executive
Pharmaceutical Executive
Closes 156d left
Resolves Jan 1, 2028, 3:00 PM UTC
Discussion
Sign in to join the discussion.